PortalPublikationenSomatostatin receptor scintigraphy in the staging of small c...

Somatostatin receptor scintigraphy in the staging of small cell lung cancer.

Standard

Somatostatin receptor scintigraphy in the staging of small cell lung cancer. / Bohuslavizki, K H; Brenner, Winfried; Günther, M; Eberhardt, J U; Jahn, N; Tinnemeyer, S; Wolf, H; Sippel, C; Clausen, M; Gatzemeier, U; Henze, E.

in: NUCL MED COMMUN, Jahrgang 17, Nr. 3, 3, 1996, S. 191-196.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bohuslavizki, KH, Brenner, W, Günther, M, Eberhardt, JU, Jahn, N, Tinnemeyer, S, Wolf, H, Sippel, C, Clausen, M, Gatzemeier, U & Henze, E 1996, 'Somatostatin receptor scintigraphy in the staging of small cell lung cancer.', NUCL MED COMMUN, Jg. 17, Nr. 3, 3, S. 191-196. <http://www.ncbi.nlm.nih.gov/pubmed/8692484?dopt=Citation>

APA

Bohuslavizki, K. H., Brenner, W., Günther, M., Eberhardt, J. U., Jahn, N., Tinnemeyer, S., Wolf, H., Sippel, C., Clausen, M., Gatzemeier, U., & Henze, E. (1996). Somatostatin receptor scintigraphy in the staging of small cell lung cancer. NUCL MED COMMUN, 17(3), 191-196. [3]. http://www.ncbi.nlm.nih.gov/pubmed/8692484?dopt=Citation

Vancouver

Bohuslavizki KH, Brenner W, Günther M, Eberhardt JU, Jahn N, Tinnemeyer S et al. Somatostatin receptor scintigraphy in the staging of small cell lung cancer. NUCL MED COMMUN. 1996;17(3):191-196. 3.

Bibtex

@article{4adc232d0cd04c608bd6ddae07fb615d,
title = "Somatostatin receptor scintigraphy in the staging of small cell lung cancer.",
abstract = "The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in the staging of patients with small cell lung cancer. Prior to chemotherapy, 20 patients were investigated up to 24 h following an injection of 200 MBq 111In-octreotide. Following chemotherapy and restaging, four patients were re-evaluated. Primary tumour was detected in 18 of 23 studies, which exhibited increasing target-to-back-ground ratios over time. Lymph node metastases and distant metastases were detected in 7 of 27 and 8 of 31 sites, respectively. Thus, the overall sensitivity for detecting metastases was less than 26%. SRS did not result in any upstaging of patients. We conclude that in patients with small cell lung cancer, functional imaging by SRS has no impact on clinical decision making.",
author = "Bohuslavizki, {K H} and Winfried Brenner and M G{\"u}nther and Eberhardt, {J U} and N Jahn and S Tinnemeyer and H Wolf and C Sippel and M Clausen and U Gatzemeier and E Henze",
year = "1996",
language = "Deutsch",
volume = "17",
pages = "191--196",
journal = "NUCL MED COMMUN",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

RIS

TY - JOUR

T1 - Somatostatin receptor scintigraphy in the staging of small cell lung cancer.

AU - Bohuslavizki, K H

AU - Brenner, Winfried

AU - Günther, M

AU - Eberhardt, J U

AU - Jahn, N

AU - Tinnemeyer, S

AU - Wolf, H

AU - Sippel, C

AU - Clausen, M

AU - Gatzemeier, U

AU - Henze, E

PY - 1996

Y1 - 1996

N2 - The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in the staging of patients with small cell lung cancer. Prior to chemotherapy, 20 patients were investigated up to 24 h following an injection of 200 MBq 111In-octreotide. Following chemotherapy and restaging, four patients were re-evaluated. Primary tumour was detected in 18 of 23 studies, which exhibited increasing target-to-back-ground ratios over time. Lymph node metastases and distant metastases were detected in 7 of 27 and 8 of 31 sites, respectively. Thus, the overall sensitivity for detecting metastases was less than 26%. SRS did not result in any upstaging of patients. We conclude that in patients with small cell lung cancer, functional imaging by SRS has no impact on clinical decision making.

AB - The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in the staging of patients with small cell lung cancer. Prior to chemotherapy, 20 patients were investigated up to 24 h following an injection of 200 MBq 111In-octreotide. Following chemotherapy and restaging, four patients were re-evaluated. Primary tumour was detected in 18 of 23 studies, which exhibited increasing target-to-back-ground ratios over time. Lymph node metastases and distant metastases were detected in 7 of 27 and 8 of 31 sites, respectively. Thus, the overall sensitivity for detecting metastases was less than 26%. SRS did not result in any upstaging of patients. We conclude that in patients with small cell lung cancer, functional imaging by SRS has no impact on clinical decision making.

M3 - SCORING: Zeitschriftenaufsatz

VL - 17

SP - 191

EP - 196

JO - NUCL MED COMMUN

JF - NUCL MED COMMUN

SN - 0143-3636

IS - 3

M1 - 3

ER -